Use access key #2 to skip to page content.
$12.07 0.31 (2.64%)
1/8/2009 4:00 PM

Affymax, Inc. (AFFY)

CAPS Rating:
**

The Company is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.

View All Commentary (AFFY)

Recs

0

Avatar ArlenesX (< 20) Submitted: 4/27/07 1:23 PM : Outperform Start Price: $34.04 AFFY Score: -25.49

IPO'd in 12/06. A great to superior market for the product, going into FDA stage 3. Once it is ok'd for sale it will reduce the dosage for anemia/cancer patients with kidney/dialysis related conditions by cutting treatment at least in half.
The potential is enormous with the market growing everyday.

Report this Post Replies: 0 | Reply | Permalink

Featured Broker Partners

Sponsored Links